See all locations for this study
Phase 1Recruiting

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsored by IDEAYA Biosciences

About this study

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Enrolling at this location

Sarah Cannon Research Institute at Florida Cancer Specialists

Orlando, Florida

I'm interested

This study also enrolls at 19 other locations. See all.

Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.

Trial data sourced from ClinicalTrials.gov.